These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

95 related articles for article (PubMed ID: 34410042)

  • 1. A Euglycemic Glucose Clamp Study to Evaluate the Bioavailability of LY2963016 Relative to Insulin Glargine in Healthy Chinese Subjects.
    Liu H; Wang F; Ji Y; Ma T; Li H; Linnebjerg H; Chua L; Tham LS; Yu Y
    Clin Pharmacol Drug Dev; 2021 Dec; 10(12):1452-1459. PubMed ID: 34410042
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comparison of the Pharmacokinetics and Pharmacodynamics of LY2963016 Insulin Glargine and EU- and US-Approved Versions of Lantus Insulin Glargine in Healthy Subjects: Three Randomized Euglycemic Clamp Studies.
    Linnebjerg H; Lam EC; Seger ME; Coutant D; Chua L; Chong CL; Ferreira MM; Soon D; Zhang X
    Diabetes Care; 2015 Dec; 38(12):2226-33. PubMed ID: 26307603
    [TBL] [Abstract][Full Text] [Related]  

  • 3. LY2963016 Insulin Glargine and Insulin Glargine (Lantus) Produce Comparable Pharmacokinetics and Pharmacodynamics at Two Dose Levels.
    Zhang X; Lam ECQ; Seger ME; Coutant D; Chua L; Tan LH; Soon D; Linnebjerg H
    Clin Pharmacol Drug Dev; 2017 Nov; 6(6):556-563. PubMed ID: 28940840
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Duration of action of two insulin glargine products, LY2963016 insulin glargine and Lantus insulin glargine, in subjects with type 1 diabetes mellitus.
    Linnebjerg H; Lam EC; Zhang X; Seger ME; Coutant D; Chua L; Kapitza C; Heise T
    Diabetes Obes Metab; 2017 Jan; 19(1):33-39. PubMed ID: 27484286
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Efficacy and safety of LY2963016 insulin glargine versus insulin glargine (Lantus) in Chinese adults with type 2 diabetes: A phase III, randomized, open-label, controlled trial.
    Feng W; Chen W; Jiang S; Du L; Zhu D
    Diabetes Obes Metab; 2021 Aug; 23(8):1786-1794. PubMed ID: 33783964
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comparable efficacy and safety between LY2963016 insulin glargine and insulin glargine (Lantus®) in Chinese patients with type 1 diabetes: A phase III, randomized, controlled trial.
    Yan X; Jiang S; Lou Y; Zhou Z
    Diabetes Obes Metab; 2021 Oct; 23(10):2226-2233. PubMed ID: 34121308
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Efficacy and Safety of LY2963016 Insulin Glargine in Chinese Patients with Type 1 Diabetes Previously Treated with Insulin Glargine (Lantus
    Yan X; Feng C; Lou Y; Zhou Z
    Diabetes Ther; 2022 Jun; 13(6):1161-1174. PubMed ID: 35471721
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparison of the pharmacokinetic and pharmacodynamic profiles of insulin degludec and insulin glargine.
    Heise T; Hövelmann U; Nosek L; Hermanski L; Bøttcher SG; Haahr H
    Expert Opin Drug Metab Toxicol; 2015; 11(8):1193-201. PubMed ID: 26086190
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comparative evaluation of pharmacokinetics and pharmacodynamics of insulin glargine (Glaritus
    Bhatia A; Tawade S; Mastim M; Kitabi EN; Gopalakrishnan M; Shah M; Yeshamaina S; Gobburu J; Sahib M; Thakur D; Prasanna Kumar KM
    Acta Diabetol; 2018 May; 55(5):461-468. PubMed ID: 29453671
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Day-to-Day and Within-Day Variability in Glucose-Lowering Effect Between Insulin Degludec and Insulin Glargine (100 U/mL and 300 U/mL): A Comparison Across Studies.
    Heise T; Kaplan K; Haahr HL
    J Diabetes Sci Technol; 2018 Mar; 12(2):356-363. PubMed ID: 28946756
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Single-dose euglycaemic clamp studies demonstrating pharmacokinetic and pharmacodynamic similarity between MK-1293 insulin glargine and originator insulin glargine (Lantus) in subjects with type 1 diabetes and healthy subjects.
    Crutchlow MF; Palcza JS; Mostoller KM; Mahon CD; Barbour AM; Marcos MC; Xu Y; Watkins E; Morrow L; Hompesch M
    Diabetes Obes Metab; 2018 Feb; 20(2):400-408. PubMed ID: 28817223
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Immunogenicity of LY2963016 insulin glargine and Lantus® insulin glargine in Chinese patients with type 1 or type 2 diabetes mellitus.
    Wang W; Song X; Lou Y; Du L; Zhu D; Zhou Z
    Diabetes Obes Metab; 2022 Jun; 24(6):1094-1104. PubMed ID: 35187770
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Evaluation of immunogenicity of LY2963016 insulin glargine compared with Lantus® insulin glargine in patients with type 1 or type 2 diabetes mellitus.
    Ilag LL; Deeg MA; Costigan T; Hollander P; Blevins TC; Edelman SV; Konrad RJ; Ortmann RA; Pollom RK; Huster WJ; Zielonka JS; Prince MJ
    Diabetes Obes Metab; 2016 Feb; 18(2):159-68. PubMed ID: 26434665
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Lilly Insulin Glargine Versus Lantus
    Pollom RK; Ilag LL; Lacaya LB; Morwick TM; Ortiz Carrasquillo R
    Diabetes Ther; 2019 Feb; 10(1):189-203. PubMed ID: 30604091
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Similar Intrapatient Blood Glucose Variability with LY2963016 and Lantus
    Nishiyama H; Shingaki T; Suzuki Y; Ilag LL
    Diabetes Ther; 2018 Aug; 9(4):1469-1476. PubMed ID: 29855972
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pharmacodynamics of the long-acting insulin analogues detemir and glargine following single-doses and under steady-state conditions in patients with type 1 diabetes.
    Koehler G; Treiber G; Wutte A; Korsatko S; Mader JK; Semlitsch B; Pieber TR
    Diabetes Obes Metab; 2014 Jan; 16(1):57-62. PubMed ID: 23841569
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pharmacokinetic and pharmacodynamic similarity evaluation between an insulin glargine biosimilar product and Lantus
    Wang Y; Zhou Y; Ding J; Li X; Guo F; Zhang J; Ding L
    Front Pharmacol; 2022; 13():962201. PubMed ID: 36091767
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Comparison of two insulin glargine formulations: biosimilar vs. reference product].
    Mönnig E; Schloot N; Hohberg C; Wiesner T; Heinemann L
    MMW Fortschr Med; 2016 Aug; 158 Suppl 5():19-27. PubMed ID: 27565486
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Single-dose pharmacokinetics and glucodynamics of the novel, long-acting basal insulin LY2605541 in healthy subjects.
    Sinha VP; Choi SL; Soon DK; Mace KF; Yeo KP; Lim ST; Howey DC
    J Clin Pharmacol; 2014 Jul; 54(7):792-9. PubMed ID: 24504686
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comparison of pharmacodynamic intrasubject variability of insulin lispro protamine suspension and insulin glargine in subjects with type 1 diabetes.
    Ocheltree SM; Hompesch M; Wondmagegnehu ET; Morrow L; Win K; Jacober SJ
    Eur J Endocrinol; 2010 Aug; 163(2):217-23. PubMed ID: 20508081
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.